Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

5 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Central sleep apnea (CSA) has been associated with increased mortality and primarily occurs in patients with heart failure (HF). The primary purpose of this study is to document the natural progression of moderate to severe CSA in heart failure patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Central Sleep Apnea Treated by CO2 Supplied by a Novel Device

NCT04907058

Central Sleep Apnea

COMPLETED NA

The Prevalence of Sleep Disordered Breathing in Hospitalized Patients With Acutely Decompensated Heart Failure Syndrome

NCT00701519

Sleep Apnea Congestive Heart Failure Heart Failure

COMPLETED

Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension

NCT05595200

Sleep Apnea Obstructive Sleep Apnea Pulmonary Hypertension +5 more

RECRUITING

Long-term Cardiovascular Outcomes in Patients With RH and OSA With or Without Treatment With CPAP

NCT03002558

Hypertension

COMPLETED

Cardiac Function After CPAP Therapy in Patients With Chronic Heart Failure and Sleep Apnea. A Multicenter Study

NCT00404807

Sleep Apnea Heart Failure Cardiovascular Diseases

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is a prospective, non-randomized observational study in heart failure patients with moderate to severe central sleep apnea (CSA).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Sleep Apnea Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational patients

Heart Failure patients with moderate to severe central sleep apnea

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is willing and able to comply with this protocol and has signed an IRB/MEC approved informed consent (as well as Privacy Protection Authorization in the United States)
* Age is greater than or equal to 18 years
* Known recent history of sleep disordered breathing of predominantly central origin, as evidenced by an overnight PSG with EEG and at least 4 hours of recording that was conducted within 60 days of enrollment and demonstrating the following characteristics:
* AHI greater than or equal to 20
* greater than or equal to 50% of classified events of a central nature
* less than 20% of the total AHI comprised of obstructive apnea events
* Diagnosed chronic heart failure, with medications optimized and stable for at least 30 days prior to the screening PSG, or since the date of the earliest test used for baseline, whichever is longer. Optimal medications include: beta blockade, ACE-I or ARB and diuretics unless contraindicated or not considered medically necessary.

Exclusion Criteria

* Current or intended use of any mask-based therapy for central sleep apnea
* Baseline oxygen saturation less than or equal to 90% on a stable FiO2
* Severe Chronic Obstructive Pulmonary Disease (COPD) (per GOLD classification system)
* History of cerebrovascular accident (CVA), myocardial infarction (MI), coronary artery bypass grafting (CABG) surgery, or percutaneous coronary intervention (PCI), or any cardiac ablation procedure within the 3 months prior to the study
* Unstable angina
* History of primary pulmonary hypertension
* Currently enrolled in a non-observational (ie, interventional) clinical study that could confound the results of this study
* If subject has an implanted cardiac resynchronization device (CRT), it must have been implanted at least 3 months before enrollment; any other device must have been implanted at least 30 days prior to enrollment
* Life expectancy of less than 6 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No